Cullinan licenses U.S. rights to B7H4 x 4-1BB bispecific CLN-418 from Harbour; cash runway into 2026

Cullinan Therapeutics, Inc.

Upfront $25M; up to $148M dev/reg milestones + $415M sales milestones plus tiered royalties up to high teens.
CLN-418/HBM7008 is a clinical-stage (Phase 1) B7H4 x 4-1BB bispecific immune activator for solid tumors.
Cash and investments $550M at end 2022; after $25M upfront would be $525M; expects cash to last into 2026.
Company expects to have six clinical-stage assets in pipeline by end 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Cullinan Therapeutics, Inc. entered into License Agreement with Harbour BioMed US Inc. valued at $25 million upfront license fee (effective 2023-02-13).

Action: entry
Agreement: license
Counterparty: Harbour BioMed US Inc.
Value: $25 million upfront license fee
Effective: 2023-02-13

Exact text from the filing

On February 13, 2023, Cullinan Oncology, Inc. (the "Company") and Harbour BioMed US Inc. ("Harbour") entered into a License and Collaboration Agreement (the "License Agreement"), pursuant to which Harbour granted to the Company an exclusive license for the development, manufacturing and commercialization of HBM7008 (CLN-418) in the U.S.

View on SEC.gov

Browse all material agreements →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-036285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.